{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:04:35Z","timestamp":1775581475906,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The main goal of this work was to identify, describe, characterize, and classify the scientific evidence regarding the use of pharmacogenomic biomarkers in antidepressant treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The work was developed in two phases: i) a search for pharmacogenomic biomarkers in summaries of antidepressant drugs with marketing authorization in Portugal; and ii) a systematic literature review based on the data obtained in the first phase, with the main objective of finding international literature that could describe and characterize previously reported biomarkers and identify other relevant biomarkers. Finally, the levels of evidence and recommendation grades were classified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 26 drugs with marketing authorization in Portugal, only 16 had pharmacogenomic information. The most widely studied pharmacogenomic biomarker was CYP2D6. These results were mostly supported by the systematic literature review, which yielded 103 papers, 63 of which were ultimately included in the review. The systematic literature review also revealed the existence of other relevant biomarkers. Most of the included studies show a good level of evidence, which guarantees reliability and good recommendation grades. For the database (built during phase i), the results were informative but resulted in no specific recommendations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Most pharmacogenomic variants are not studied or acknowledged by genetic tests, and more scientific research is needed to confirm their usefulness. Therefore, only a small number of variants are considered when prescribing antidepressant drugs. In addition, genotyping of patients is not common in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04225-2","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T05:02:38Z","timestamp":1661835758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Catarina","family":"Correia","sequence":"first","affiliation":[]},{"given":"Luciano","family":"Alcobia","sequence":"additional","affiliation":[]},{"given":"Manuel Jos\u00e9","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Ana Margarida","family":"Advinha","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"4225_CR1","doi-asserted-by":"publisher","unstructured":"Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020;25(2):321-38. https:\/\/doi.org\/10.1038\/s41380-019-0585-z.","DOI":"10.1038\/s41380-019-0585-z"},{"key":"4225_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neubiorev.2019.07.021","volume":"105","author":"FS de Aguiar Neto","year":"2019","unstructured":"de Aguiar Neto FS, Rosa JLG. Depression biomarkers using non-invasive EEG: a review. Neurosci Biobehav Rev. 2019;105:83\u201393. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.07.021.","journal-title":"Neurosci Biobehav Rev"},{"key":"4225_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jad.2017.07.001","volume":"233","author":"BS Gadad","year":"2018","unstructured":"Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP, et al. Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J Affect Disord. 2018;233:3\u201314. https:\/\/doi.org\/10.1016\/j.jad.2017.07.001.","journal-title":"J Affect Disord"},{"issue":"6","key":"4225_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14737159.2018.1470927","volume":"18","author":"C Mora","year":"2018","unstructured":"Mora C, Zonca V, Riva MA, Cattaneo A. Blood biomarkers and treatment response in major depression. Expert Rev Mol Diagn. 2018;18(6):513\u201329. https:\/\/doi.org\/10.1080\/14737159.2018.1470927.","journal-title":"Expert Rev Mol Diagn"},{"key":"4225_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/164_2018_171","volume":"250","author":"MK Jha","year":"2019","unstructured":"Jha MK, Trivedi MH. Pharmacogenomics and biomarkers of depression. Handb Exp Pharmacol. 2019;250:101\u201313.","journal-title":"Handb Exp Pharmacol"},{"key":"4225_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tips.2010.11.008","volume":"32","author":"SC Sim","year":"2011","unstructured":"Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011;32:72\u201381.","journal-title":"Trends Pharmacol Sci"},{"key":"4225_CR7","doi-asserted-by":"publisher","unstructured":"Lozupone M, La Montagna M, D\u2019Urso F, Daniele A, Greco A, Seripa D, et al. The Role of Biomarkers in Psychiatry. In: Guest P, editor. Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders Advances in Experimental Medicine and Biology, vol 1118. Springer, Cham.; 2019. p. 135\u201362. https:\/\/doi.org\/10.1007\/978-3-030-05542-4_7.","DOI":"10.1007\/978-3-030-05542-4_7"},{"issue":"1","key":"4225_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41398-019-0521-7","volume":"9","author":"L Carboni","year":"2019","unstructured":"Carboni L, McCarthy DJ, Delafont B, Filosi M, Ivanchenko E, Ratti E, et al. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry. 2019;9(1):182. https:\/\/doi.org\/10.1038\/s41398-019-0521-7.","journal-title":"Transl Psychiatry"},{"key":"4225_CR9","volume-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews, vol. 372. The BMJ: BMJ Publishing Group; 2021."},{"key":"4225_CR10","unstructured":"Oxford Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) [Internet]. 2022 [cited 2022 Feb 25]. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"key":"4225_CR11","unstructured":"U.S. Food & Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling [Internet]. 2022 [cited 2022 Feb 25]. Available from: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"issue":"0","key":"4225_CR12","first-page":"18","volume":"0","author":"JK Hicks","year":"2019","unstructured":"Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, et al. A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant pharmacotherapy. Clin Pharmacol Ther. 2019;0(0):18\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4225_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1176\/appi.ajp.2018.18020134","volume":"175","author":"JC Stingl","year":"2018","unstructured":"Stingl JC. Mindful pharmacogenetics: drug dosing for mental health. Am J PsychiatryAm J Psychiatry. 2018;175(5):395\u20137.","journal-title":"Am J PsychiatryAm J Psychiatry."},{"key":"4225_CR14","volume-title":"Effect of Polymorphisms on the Pharmacokinetics Pharmacodynamics and Safety of Sertraline in Healthy Volunteers","author":"M Saiz-Rodr\u00edguez","year":"2017","unstructured":"Saiz-Rodr\u00edguez M, Belmonte C, Ochoa D, Koller D, Cabaleiro T, Abad-santos F. Effect of Polymorphisms on the Pharmacokinetics Pharmacodynamics and Safety of Sertraline in Healthy Volunteers. 2017."},{"key":"4225_CR15","volume-title":"Venlafaxine pharmacogenetics: a comprehensive review Pharmacogenomics","author":"J Suwa-la","year":"2019","unstructured":"Suwa-la J, Machowska M, Wiela-Hojenska A. Venlafaxine pharmacogenetics: a comprehensive review Pharmacogenomics. 2019."},{"key":"4225_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","volume":"31","author":"MEE Shams","year":"2006","unstructured":"Shams MEE, Arneth B, Hiemke C, Dragicevic A, Kaiser R, Lackner K, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493\u2013502.","journal-title":"J Clin Pharm Ther"},{"key":"4225_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13651500410005559","volume":"8","author":"F Haller-Gloor","year":"2004","unstructured":"Haller-Gloor F, Eap CB, Turgeon J, Baumann P. High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. Int J Psychiatry Clin Pract. 2004;8:191\u20135.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"4225_CR18","doi-asserted-by":"publisher","unstructured":"Hicks J, Sangkuhl K, Swen J, Ellingrod V, M\u00fcller D, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37\u201344.  https:\/\/doi.org\/10.1002\/cpt.597.","DOI":"10.1002\/cpt.597"},{"issue":"1","key":"4225_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40246-019-0229-z","volume":"13","author":"K Krebs","year":"2019","unstructured":"Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics. 2019;13(1):39.","journal-title":"Hum Genomics."},{"key":"4225_CR20","volume-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Ji Y, Susan G, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. 2015."},{"issue":"8","key":"4225_CR21","first-page":"726","volume":"24","author":"EJ Groessl","year":"2018","unstructured":"Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm. 2018;24(8):726\u201334.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04225-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T05:09:58Z","timestamp":1661836198000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04225-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4225"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04225-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"576"}}